K. Viraswami-Appanna

Muraglitazar, a dual (α/γ) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

J. Buse, J. Davidson, R. Frederich, 2005 .

Bias Assessment in Progression-Free Survival Analysis Using Interval-Censored Methods

B. Dharan, K. Viraswami-Appanna, C. Hu, 2012 .

Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes

F. Fiedorek, C. Rubin, K. Viraswami-Appanna, 2009, Diabetes & vascular disease research.

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

J. Buse, J. Davidson, R. Frederich, 2005, Clinical therapeutics.

Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naïve Patients With ALK-Rearranged Non-Small-Cell Lung Cancer.

G. Scagliotti, A. Shaw, Keunchil Park, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

G. Scagliotti, Serafino Pantano, C. Gridelli, 2017, The Lancet. Oncology.

Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial

R. Salazar, J. Tabernero, B. Melichar, 2011, British Journal of Cancer.

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.

P. Postmus, Keunchil Park, R. Dziadziuszko, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer

M. Shi, Yvonne Y. Lau, W. Gu, 2017, Cancer Chemotherapy and Pharmacology.

Journal Pre-proof Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALK i-Naïve Patients With ALK -Rearranged Non–Small-Cell Lung Cancer Phase II Study of in i-Naïve Patients With ALK -Rearranged Non–Small-Cell

A. Shaw, E. Felip, D. Spigel, 2019 .